Your browser is out of date. It has known security flaws and may not display all features of this and other websites.
Learn how to update your browser.
Access to our campus and services is currently modified due to the coronavirus public health crisis. For the latest updates on evolving COVID-19 policies and resources for our campus community, click here.

Notice of Third-Party Vendor Data Breach Affecting CWSL Data

Robert A. Bohrer

Professor of Law

LL.M. Harvard University
J.D. University of Illinois
B.A. Haverford College [psychology]
225 Cedar Street
(619) 525-1435
Biotechnology Seminar, Food and Drug Law, Torts II

Professor Bohrer practiced with the Chicago law firm of Bell, Boyd & Lloyd before returning to academia. Although he has written about such varied topics as the constitutionality of I.Q. testing in the public schools, congressional control of affirmative action, and the risks of toxic substances, since 1984 he has focused primarily on the legal issues raised by developments in biotechnology and pharmaceutical policy.

Professor Bohrer is a member of the executive board of the Biolaw Section of the AALS and previously served on the Council of the ABA Section of Science and Technology. Bohrer was executive editor of Biotechnology Law Report from 1999 to 2011. He previously served as director of Biotechnology Programs at the University of California at San Diego's Center for Molecular Genetics and and on the board of directors of the La Jolla Institute for Molecular Medicine. Bohrer was the only law professor to serve on the board of directors of the Biotechnology Institute of the U.S. Patent and Trademark Office. While in law school at Illinois, he was a member of Law Review and a teaching assistant in the College of Commerce.


  • Robert A. Bohrer, A Guide to Biotechnology Law and Business (Carolina Academic Press 2007).


  • Robert A. Bohrer, Reach-Through Patent Claims to Drug Targets: An Rx for Pharmaceutical Policy, 26 Nature Biotechnology 55 (2008).

Scholarly Presentations

  • "Pharmaceutical Policy and Public Health: An Information Prescription for Pharmaceutical Policy," presented to the American Society for Law, Medicine & Ethics Health Law Professors Conference, Austin, TX, June 4, 2010.
  • "The Reverse Doctrine of Equivalents to Limit Reach- Through Claims to Drug Target Patents," presented to The 2010 Intellectual Property Scholars Roundtable, Drake University Law School, Des Moines, IA, March 26, 2010.
  • "Why is this drug different from all the other drugs? An agenda for law and pharmaceutical policy," presented to the Division of Pharmacoepidemiology and Pharmacoeconomics, Brigham and Women’s Hospital, Boston, MA, December 11th 2009.
  • "Ethical Issues: Longevity Research and Clinical Trials," Biotechnology Law 2005, Practicing Law Institute California Center, November 2005, San Francisco, CA.
  • "Recent Developments in Patent Law: What do they Mean for University Researchers?" Summer Neuropeptide Society Meeting, July 2005, Miami Beach, CA.
  • "Applying Ethical Reasoning in the Debate Over Social Policy: Embryonic Stem Cell Research," Lawyers' Club, March 2005, San Diego, CA.